Opinion

Video

Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

Author(s):

Guillermo Garcia-Manero, MDRami Komrokji, MD

Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.

  1. Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy?
    1. Real-world dose escalation and outcomes of luspatercept across all LOTs (Patel K, et al. EHA 2024. Abstract P768.)
    2. IMerge study, PROs in heavily pre-treated patients with LR-MDS: Sekeres MA, et al. Blood. 2023; 142 (suppl 1):6479.
    3. Real World Data Replicates Medalist Study Results (Komrokji RS et al. Blood 2022)
  2. Can each of you share any key takeaways or additional data updates surrounding lower-risk MDS presented at EHA 2024? (if time permits)
  3. Let’s discuss novel agents and/or combination strategies in LR-MDS through ongoing research that may shape the future treatment landscape.
    1. Luspatercept plus erythropoietin in LR-MDS: Jonasova A, et al. EHA 2024. Abstract P1886.
    2. Luspatercept plus ESA combinations in LR-MDS: Komrokji RS, et al. Blood Adv. 2023.
    3. Ph 2 study, elritercept (KER-050): Díez Campelo M, et al. EHA 2024. Abstract S183.
Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 5 experts on CLL
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment